Seattle Genetics | SGEN - Koszty Sprzedaży I Administracji



Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.58B 316M 2026-03
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amgen USD 1.58B 354M 2026-03
Astellas Pharma JPY 234.7B 12.92B 2026-03
Bayer EUR 3.7B 356M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Celldex Therapeutics USD 11.45M 3.61M 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eisai JPY 119.54B 7.82B 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Genmab DKK 208M 60M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 328.1M 62.31M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Takeda JPY 292B 9.21B 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xencor USD 82.12M 65.08M 2026-03